Market reviews 2021

Published on 10 February 2022

Review of the Finnish human pharmaceuticals market

Finland is the most important individual market for Orion, generating more than a quarter of the Group’s net sales. According to Pharmarket statistics (1–12/2021), the total sales of Orion’s human pharmaceuticals in January-December 2021, including both medicinal and non-medicinal products, grew by 3 per cent from the previous year, like the market. The incidence of seasonal illnesses, such as common respiratory tract infections, was below normal especially in the first half of the year, resulting in lower full-year market sales in self-care products.

Orion’s biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion’s reference-priced prescription drugs increased by 5 per cent due to strong volume growth while the total market fell by 4 per cent from the comparison period. The average price of reference-priced drugs in the market declined by approximately 9% from the comparative period (Source: Pharmarket). The impact of constant price competition on Orion has been significant due to the Company’s broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference-priced prescription drugs and self-care products, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products): 

EUR million

 

1-12/21

1-12/20

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

2,984

2,904

+3%

Orion

 

324

316

+3%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

1,696

1,646

+3%

Orion

188

182

+3%

Reference priced prescription drugs (pharmacy channel) *

 

Market

433

451

-4%

Orion

116

111

+5%

Self-care products (pharmacy channel)

 

Market

 

403

404

-0%

Orion

 

102

105

-2%

 

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.

Source: Pharmarket sales statistics 1-12/2021

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Orion’s market share, %

1-12/21

1-12/20

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

11%

Prescription drugs total (pharmacy channel)

11%

11%

Reference priced prescription drugs (pharmacy channel) *

27%

25%

Self-care products (pharmacy channel)

25%

26%


* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.                                      

Source: Pharmarket sales statistics 1-12/2021

Published on 20 October 2021

Review of the Finnish human pharmaceuticals market

Finland is the most important individual market for Orion, generating more than a quarter of the Group’s net sales. According to Pharmarket statistics (1–9/2021), the total sales of Orion’s human pharmaceuticals in January-September 2021, including both medicinal and non-medicinal products, were at the previous year’s level. The incidence of seasonal illnesses, such as common respiratory tract infections, was below normal especially in the first half of the year, resulting in lower than normal market volumes in self-care products. Since summer, gradual recovery has been evident in the market.

Orion’s biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion’s reference-priced prescription drugs increased by 3 per cent due to strong volume growth while the total market fell by 5 per cent from the comparison period. The average price of reference-priced drugs in the market declined by approximately 8% from the comparative period (Source: Pharmarket). The impact of constant price competition on Orion has been significant due to the Company’s broad product range and significant market share in Finland. 

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference-priced prescription drugs and self-care products, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

 

EUR million

 

1-9/21

1-9/20

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

2,171

2,122

+2%

Orion

 

236

230

+2%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

1,218

1,188

+3%

Orion

136

131

+4%

Reference priced prescription drugs (pharmacy channel) *

 

Market

325

341

-5%

Orion

79

76

+3%

Self-care products (pharmacy channel)

 

Market

 

298

304

-2%

Orion

 

75

77

-2%

 

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.

Source: Pharmarket sales statistics 1-9/2021

 

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

 

Orion’s market share, %

1-9/21

1-9/20

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

11%

Prescription drugs total (pharmacy channel)

11%

11%

Reference priced prescription drugs (pharmacy channel) *

24%

22%

Self-care products (pharmacy channel)

25%

25%


* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.                                                               

Source: Pharmarket sales statistics 1-9/2021

Published on 19 July 2021

Review of the Finnish human pharmaceuticals market

Finland is the most important individual market for Orion, generating more than a quarter of the Group's net sales. According to Pharmarket statistics (1–6/2021), the total sales of Orion's human pharmaceuticals in January-June 2021, including both medicinal and non-medicinal products, were at the previous year's level. The prevalence of seasonal illnesses such as common respiratory tract infections has been lower than normal due to which the market volumes were lower than normal especially in the self-care products.

Orion's biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion's reference-priced prescription drugs increased, while the total market fell from the comparison period. The average price of reference-priced drugs in the market declined by approximately 8% from the comparative period (Source: Pharmarket). The impact of constant price competition on Orion has been significant due to the Company's broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference-priced prescription drugs and self-care products, with its market share being a quarter of the market in each. 

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

EUR million

 

1-6/21

1-6/20

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

1,426

1,421

+0%

Orion

 

154

154

+0%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

789

782

+1%

Orion

89

87

+2%

Reference priced prescription drugs (pharmacy channel) *

 

Market

215

228

-6%

Orion

51

50

+2%

Self-care products (pharmacy channel)

 

Market

 

197

207

-5%

Orion

 

49

53

-7%

 

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.  

Source: Pharmarket sales statistics 1-6/2021

 

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Orion’s market share, %

1-6/21

1-6/20

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

11%

Prescription drugs total (pharmacy channel)

11%

11%

Reference priced prescription drugs (pharmacy channel) *

24%

22%

Self-care products (pharmacy channel)

25%

25%


* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.                                                                                                                                                    

Source: Pharmarket sales statistics 1-6/2021

Published on 27 April 2021

Review of the Finnish human pharmaceuticals market

Finland is the most important individual market for Orion, generating more than a quarter of the Group's net sales. According to Pharmarket statistics (1–3/2021), the total sales of Orion's human pharmaceuticals in January-March 2021, including both medicinal and non-medicinal products, declined faster than the market. The overall market decline is largely explained by a strong comparative period, during which COVID-19 increased demand notably. The prevalence of seasonal illnesses such as the common flu has been lower than normal due to which the market volumes were lower than normal especially in the self-care products.

Orion's biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion's reference-priced prescription drugs fell from the review period slower than the market. The average price of reference-priced drugs in the market declined approximately 5% from the comparative period (Source: Pharmarket). The impact of constant price competition on Orion has been significant due to the Company's broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference-priced prescription drugs and self-care products, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

 

EUR million

 

1-3/21

1-3/20

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

698

750

-7%

Orion

 

75

86

-13%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

378

398

-5%

Orion

43

46

-8%

Reference priced prescription drugs (pharmacy channel) *

 

 

 

Market

101

113

-10%

Orion

25

27

-7%

Self-care products (pharmacy channel)

 

 

 

Market

 

100

119

-16% 

Orion

 

25

30

-18% 

 

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.

   

Source: Pharmarket sales statistics 1-3/2021

 

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

 

Orion’s market share, %

1-3/21

1-3/20

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

11%

Prescription drugs total (pharmacy channel)

11%

12%

Reference priced prescription drugs (pharmacy channel) *

24%

24%

Self-care products (pharmacy channel)

25%

26%


* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.                                                                                                                                        

Source: Pharmarket sales statistics 1-3/2021